Zymeworks Inc
ZYMEHealthcare|Biotechnology|USA
$25.88
-1.19 (-4.40%)
Tangible Book
$2.04
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05615818 Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms | P3 | Recruiting | 800 | RCT, Open-label | Futibatinib, Ivosidenib, Zanidatamab, Trastuzumab, Neratinib, Encorafenib, Binimetinib, Niraparib, Cisplatin, Gemcitabine |
| NCT05035836 A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Breast Cancer, HER2-positive | P2 | Recruiting | 20 | Open-label | Zanidatamab, Letrozole, Tamoxifen |
| NCT06555744 A Study of ZW191 in Participants With Solid Tumors | Advanced Solid Tumors | P1 | Active | 145 | Open-label | ZW191 |
| NCT07164313 A Study of ZW251 in Participants With Advanced Solid Tumors | Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer | P1 | Recruiting | 100 | Open-label | ZW251 |
| NCT04513665 ZW25 in Women With Endometrial Cancers | Endometrial Cancer, Carcinosarcoma | P2 | Completed | 16 | Open-label | ZW25 |
| NCT03821233 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | HER2-expressing Cancers | P1 | Completed | 112 | Open-label | ZW49 |
| NCT06523803 A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers | Mesothelin-expressing Advanced Cancers | P1 | Terminated | 32 | Open-label | ZW171 |